Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

Results

Save Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial	Phase	Eligible Participant	Official Title	Drugs in Trial	Location
NCT03038100	III	Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)	A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03180307	III	Newly diagnosed stage III ovarian cancer	A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer	View Drugs	Arizona, California, Florida, Maryland, Michigan, Minnesota, Missouri, Ohio, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action OTL38 fluorescent imaging ligand OTL38 Folate receptor imaging agent
NCT03642132	III	Newly diagnosed stage III/IV non-mucinous ovarian epithelial cancer (neo-adjuvant or adjuvant and maintenance)	A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab In Combination With Chemotherapy Followed By Maintenance Therapy Of Avelumab In Combination With The Poly (Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Previously Untreated Advanced Ovarian Cancer (Javelin Ovarian Parp100)	View Drugs	Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, New Jersey, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Talazoparib Talazoparib Tosylate, BMN-673, MDV3800 PARP inhibitor
NCT03602859	III	Newly diagnosed stage III/IV non-mucinous ovarian epithelial cancer (neo-adjuvant or adjuvant and maintenance)	ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer	View Drugs	Alaska, California, Connecticut, Florida, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, Montana, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Niraparib MK4827, Zejula PARP inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor TSR-042 ANB011, anti-PD-1 monoclonal antibody TSR-042 Blocks PD-L1/2 inhibition of T cells
NCT03737643	III	Newly diagnosed stage III/IV high grade non-mucinous epithelial ovarian cancer (neo-adjuvant or adjuvant and maintenance)	A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).	View Drugs	California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri, Nevada, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Durvalumab Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Olaparib AZD2281, Lynparza PARP inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02437812	II	Newly diagnosed stage II-IV ovarian cancer	A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Metformin Fortamet, Glucophage, Glumetza, Riomet AMP-activated protein kinase (AMPK) activator Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02520154	II	Newly diagnosed stage III/IV high grade non-mucinous ovarian epithelial cancer (neo-adjuvant)	Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02834975	II	Newly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)	Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02766582	II	Newly diagnosed stage III/IV ovarian cancer after suboptimal debulking surgery	Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer	View Drugs	Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02033616	II	Newly diagnosed stage III/IV ovarian cancer	Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action TAA-loaded autologous dendritic cell vaccine Anti-tumor immune response
NCT03531645	II	Newly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant)	Pilot Translation Study of Neoadjuvant Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Fulvestrant Faslodex, ICI 182,780, ZD9238 ER antagonist (SERD) Palbociclib Ibrance, PD0332991, PD-0332991 CDK4/6 inhibitor
NCT03206645	Ib	Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)	Phase IB Study of Weekly Paclitaxel + Carboplatin With the BMI-1 Inhibitor PTC596 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy	View Drugs	Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor PTC596 polycomb ring finger oncogene inhibitor PTC596, BMI1 inhibitor PTC596 BMI1 inhibitor
NCT03206177	Ib	Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma	Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary	View Drugs	Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Galunisertib LY2157299 TGFBR1 antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02713386	I/II	Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)	A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	View Drugs	Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Ruxolitinib INCB18424, Jakafi, oral Janus-associated kinase inhibitor INCB18424, oral JAK inhibitor INCB18424 JAK1/2 kinase inhibitor
NCT02726997	I/II	Newly diagnosed stage III/IV high grade non-mucinous epithelial ovarian cancer (neo-adjuvant)	Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent Durvalumab Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03394885	I/II	Newly diagnosed stage III-IV ovarian cancer (neo-adjuvant; inc expansion)	Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer	View Drugs	North Carolina
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03393884	I/II	Newly diagnosed stage III/IV epithelial ovarian cancer (neo-adjuvant)	A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	View Drugs	Alabama, California, Florida, Massachusetts, Missouri, New Jersey, New York, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplatin, Novoplatinum DNA damaging agent GEN-1 phIL-12-005/PPC, EGEN-001, PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02933073	I	Newly diagnosed stage III/IV epithelial ovarian cancer or platinum sensitive ovarian cancer at first recurrence	A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma	View Drugs	Connecticut
Drug(s) in Trial Other Drug Names Main Known Action OncoImmunome Anti-tumor immune response
NCT03607955	I	Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant)	Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy	View Drugs	Missouri, Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action AVB-S6-500 GAS6 antagonist Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor